These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Zinc aspartate suppresses T cell activation in vitro and relapsing experimental autoimmune encephalomyelitis in SJL/J mice. Stoye D; Schubert C; Goihl A; Guttek K; Reinhold A; Brocke S; Grüngreiff K; Reinhold D Biometals; 2012 Jun; 25(3):529-39. PubMed ID: 22350510 [TBL] [Abstract][Full Text] [Related]
3. Combined Treatment with Zinc Aspartate and Intravenous Immunoglobulins (IVIGs) Ameliorates Experimental Autoimmune Encephalomyelitis (EAE). Straubel D; Thielitz A; Reinhold A; Grüngreiff K; Reinhold D J Immunol Res; 2018; 2018():5982169. PubMed ID: 30356433 [TBL] [Abstract][Full Text] [Related]
4. Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. Brod SA; Khan M J Autoimmun; 1996 Feb; 9(1):11-20. PubMed ID: 8845048 [TBL] [Abstract][Full Text] [Related]
5. Euphol prevents experimental autoimmune encephalomyelitis in mice: evidence for the underlying mechanisms. Dutra RC; de Souza PR; Bento AF; Marcon R; Bicca MA; Pianowski LF; Calixto JB Biochem Pharmacol; 2012 Feb; 83(4):531-42. PubMed ID: 22155310 [TBL] [Abstract][Full Text] [Related]
6. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762 [TBL] [Abstract][Full Text] [Related]
7. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression. Imler TJ; Petro TM Int Immunopharmacol; 2009 Jan; 9(1):134-43. PubMed ID: 19022403 [TBL] [Abstract][Full Text] [Related]
8. Oral flavonoids delay recovery from experimental autoimmune encephalomyelitis in SJL mice. Verbeek R; van Tol EA; van Noort JM Biochem Pharmacol; 2005 Jul; 70(2):220-8. PubMed ID: 15946653 [TBL] [Abstract][Full Text] [Related]
9. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. II. Fine specificity of effector T cell inhibition. Tan LJ; Kennedy MK; Miller SD J Immunol; 1992 May; 148(9):2748-55. PubMed ID: 1374098 [TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory effects of licochalcone A on experimental autoimmune encephalomyelitis. Fontes LB; Dos Santos Dias D; de Carvalho LS; Mesquita HL; da Silva Reis L; Dias AT; Da Silva Filho AA; do Amaral Corrêa JO J Pharm Pharmacol; 2014 Jun; 66(6):886-94. PubMed ID: 24447171 [TBL] [Abstract][Full Text] [Related]
11. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Kebir H; Ifergan I; Alvarez JI; Bernard M; Poirier J; Arbour N; Duquette P; Prat A Ann Neurol; 2009 Sep; 66(3):390-402. PubMed ID: 19810097 [TBL] [Abstract][Full Text] [Related]
13. Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Meyer AL; Benson JM; Gienapp IE; Cox KL; Whitacre CC J Immunol; 1996 Nov; 157(9):4230-8. PubMed ID: 8892661 [TBL] [Abstract][Full Text] [Related]
14. Cytokine production profiles in chronic relapsing-remitting experimental autoimmune encephalomyelitis: IFN-γ and TNF-α are important participants in the first attack but not in the relapse. Hidaka Y; Inaba Y; Matsuda K; Itoh M; Kaneyama T; Nakazawa Y; Koh CS; Ichikawa M J Neurol Sci; 2014 May; 340(1-2):117-22. PubMed ID: 24655735 [TBL] [Abstract][Full Text] [Related]
15. Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis. Matejuk A; Bakke AC; Hopke C; Dwyer J; Vandenbark AA; Offner H J Neurosci Res; 2004 Jul; 77(1):119-26. PubMed ID: 15197745 [TBL] [Abstract][Full Text] [Related]
16. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model. Jung EJ; Hur M; Kim YL; Lee GH; Kim J; Kim I; Lee M; Han HK; Kim MS; Hwang S; Kim S; Woo AM; Yoon Y; Park HJ; Won J J Pharmacol Exp Ther; 2009 Dec; 331(3):1005-13. PubMed ID: 19741152 [TBL] [Abstract][Full Text] [Related]
17. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. Racke MK; Burnett D; Pak SH; Albert PS; Cannella B; Raine CS; McFarlin DE; Scott DE J Immunol; 1995 Jan; 154(1):450-8. PubMed ID: 7527821 [TBL] [Abstract][Full Text] [Related]
18. Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis. Mitchell KM; Dotson AL; Cool KM; Chakrabarty A; Benedict SH; LeVine SM Mult Scler; 2007 Nov; 13(9):1118-26. PubMed ID: 17967839 [TBL] [Abstract][Full Text] [Related]
19. T cell-depleted splenocytes from mice pre-immunized with neuroantigen in incomplete Freund's adjuvant involved in protection from experimental autoimmune encephalomyelitis. Zheng H; Zhang H; Liu F; Qi Y; Jiang H Immunol Lett; 2014; 157(1-2):38-44. PubMed ID: 24220208 [TBL] [Abstract][Full Text] [Related]
20. An acidic polysaccharide of Panax ginseng ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells. Hwang I; Ahn G; Park E; Ha D; Song JY; Jee Y Immunol Lett; 2011 Aug; 138(2):169-78. PubMed ID: 21524666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]